TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35038165
Drug: Sham subcutaneous
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham subcutaneous injection of normal saline
Study: 34127273
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with AChEI medications (sham-taper group)
Study: 34127273
Drug: Treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment discontinuation via tapering (real-taper group)
Study: 34127273
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (sham-taper and real-taper)
Study: 37882059
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg)
Study: 36246996
Drug: Perioperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative intravenous amiodarone infusion
Study: 33431619
Drug: Conservative medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative medical treatment
Study: 38803637
Drug: Tablet
Normalized name: TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: 32320007
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioral therapy
Study: 33054695
Drug: Breakfast containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast containing 20% of the total recommended daily calories
Study: 34293304
Drug: Semaglutide 2·0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 2·0 mg
Study: 33765335
Drug: Gemtuzumab ozogamycin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamycin (GO) 6 mg/m2 added to standard chemotherapy
Study: 37755371
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (EOF)
Study: 35288386
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise training (RET) combined with leucine and vitamin D-enriched whey protein-based oral nutritional supplement (2 times per day) for 13 weeks plus usual care
Study: 35291004
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, Arm 1)
Study: 34468869
Drug: Paclitaxel (standard-dose)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (standard-dose)
Study: 32164762
Drug: Peficitinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peficitinib (100 mg, or 50 mg for patients transferring from RAJ1), administered orally once daily
Study: 33370847
Drug: Stabilised aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilised aqueous silver fluoride solution (AgF) with Potassium Iodide (KI)
Study: 33493023
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of hemp protein (hemp40)
Study: 33493023
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of hemp protein (hemp20)
Study: 36517849
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment (MMT)
Study: 34195577
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 mg orally twice daily, reduced to once daily if eGFR was reduced)
Study: 35180719
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod (6.25 mg 3 times weekly for 8 to 16 weeks)
Study: 33651671
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg, two infusions administered two weeks apart)
Study: 32739962
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) 266 mg plus bupivacaine HCl 50 mg
Study: 32739962
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 50 mg alone
Study: 33446506
Drug: 2.5-cm 22G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-cm 22G peripheral intravenous catheter (PIVC)
Study: 35236778
Drug: Postbiotic lozenge
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postbiotic lozenge
Study: 34587302
Drug: Tenofovir amibufenamide
Normalized name: Tenofovir amibufenamide
DrugBank: Tenofovir amibufenamide (DB18805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir amibufenamide (TMF) 25 mg
Study: 34919250
Drug: Myo-Inositol (myo-Ins)
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-Inositol (myo-Ins) plus Oral Contraceptive Pills (OCP)
Study: 34514929
Drug: Etanercept weekly
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept weekly (n=34)
Study: 32617061
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid therapy
Study: 33738704
Drug: 3% melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% melatonin oral gel
Study: 32690074
Drug: Nasal irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal irrigation with budesonide (1mg/2mL diluted in 250mL of physiological saline 9°/00) for 30 days, along with olfactory rehabilitation twice a day.
Study: 32690074
Drug: Nasal irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal irrigation with physiological saline 9°/00 only for 30 days, along with olfactory rehabilitation twice a day.
Study: 34547450
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (MT)
Study: 33938371
Drug: 6‐(Methylsulfinyl)hexyl isothiocyanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐(Methylsulfinyl)hexyl isothiocyanate (6‐MSITC) 9 mg/day
Study: 34799113
Drug: Acetaminophen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (50 mg/kg of BW) mixed with MR
Study: 34799113
Drug: Feeding frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feeding frequency and feeding rate treatments
Study: 33126931
Drug: Intervention involving
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention involving in-service training provided by nurses, work process organisation, and additional clinic-specific solutions in six clinics.
Study: 32692216
Drug: Modified Dachengqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Dachengqi decoction combined with conventional therapy
Study: 33087178
Drug: 7-session online
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-session online cognitive behavioral therapy (CBT) program
Study: 32605909
Drug: Standard-dose pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose pembrolizumab plus reduced-dose ipilimumab
Study: 33601921
Drug: Aspirin, Enoxaparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, Enoxaparin, Warfarin
Study: 33758499
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (90 mg ticagrelor tablets) under fed conditions
Study: 33758499
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (90 mg ticagrelor tablets) under fasting conditions
Study: 33758499
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (90 mg ticagrelor tablets) under fed conditions
Study: 33826785
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid 250 mg twice daily for three months
Study: 33826785
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid combined with topical hydroquinone 4% cream
Study: 33826785
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid combined with two sessions of 1064 nm low-fluence Q-switched Nd:YAG laser
Study: 32033908
Drug: Palucorcel (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palucorcel (3.0 × 10^5 cells in 50 μl) administered via subretinal injection
Study: 32876714
Drug: Pudendal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal block with ropivacaine 7.5 mg/ml
Study: 32251064
Drug: Generalized linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generalized linear model for the conditional mean of the mediator given treatment and baseline confounders.
Study: 32251064
Drug: Education as
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education as a treatment variable.
Study: 33025051
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg)
Study: 33036701
Drug: MI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI plus ω‐3 (800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid/day)
Study: 33546963
Drug: Cleaning routines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleaning routines with and without daily and/or weekly cleaners
Study: 32573956
Drug: TAS-303 8-18
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-303 8-18 mg
Study: 33030881
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol plus Foley bulb (100 micrograms)
Study: 35211010
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine at 1 μg.kg−1
Study: 35211010
Drug: Oral dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexmedetomidine at 4 μg.kg−1
Study: 33188392
Drug: Dietary concentration
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary concentration of ergovaline: 0, 0.862, and 1.282 mg/kg of diet (experiment 1)
Study: 33188392
Drug: Endophyte-infected seeds
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endophyte-infected seeds providing ergovaline dosage of 15 μg/kg BW (experiment 2)
Study: 35150143
Drug: Nano-curcumin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (160 mg for 10 days)
Study: 36199630
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg lidocaine (L0.5)
Study: 32572778
Drug: Citrus aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus aurantium essential oil inhalation for 15–20 min about 60 min before angiography
Study: 32572778
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water inhalation (control group)
Study: 32768315
Drug: High EAA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High EAA (0.3 g/kg, 23.5 ± 2.54 g)
Study: 32768315
Drug: Standard EAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard EAA (0.1 g/kg, 7.87 ± 0.87 g)
Study: 32241789
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment
Study: 35917753
Drug: Waitlist with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist with treatment advice (WL/TA)
Study: 33610906
Drug: Compassionate Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassionate Focused Therapy (CFT)
Study: 35428718
Drug: MTX+ETN combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX+ETN combination therapy
Study: 35421019
Drug: Camelina sativa
Normalized name: CAMELINA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camelina sativa oil (CSO) supplement for 12 weeks
Study: 33074284
Drug: Rivaroxaban, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban, 15 mg daily
Study: 35178708
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual alone
Study: 32065623
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg zilucoplan SC daily
Study: 32065623
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg zilucoplan
Study: 32065623
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg zilucoplan
Study: 39730078
Drug: digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: digital cognitive behavioral therapy for insomnia (dCBT-I)
Study: 35788070
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (daily tablet for 6 months)
Study: 35788070
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily tablet for 6 months)
Study: 33620905
Drug: Nitrofurantoin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (100 mg) twice-daily for 5 days
Study: 33620905
Drug: Placebo twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo twice-daily for 5 days
Study: 32430459
Drug: Drugs (fostamatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs (fostamatinib, zinc)
Study: 34684525
Drug: Salmon (246
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon (246 g fillet/day for 8 weeks, 3 days per week)
Study: 34684525
Drug: Yellowstripe scad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellowstripe scad (385 g whole fish/day for 8 weeks, 3 days per week)
Study: 33263234
Drug: CEF (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (125 mg/quarter intramammary)
Study: 33764324
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone 100 mg/d for 8 weeks
Study: 32464280
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily for 3 weeks on/1 week off
Study: 39468623
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy
Study: 36261594
Drug: Structured Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Water Dance Intervention (SWAN), administered for 40 minutes once a week during a 12-week period.
Study: 33839923
Drug: Anemia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia group (hemoglobin < 12 g/dL for women and < 13 g/dL for men)
Study: 32618212
Drug: Group Music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Music (GM) - 30-minute musical intervention before chemotherapy
Study: 34560835
Drug: Remifentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil plasma target concentration 0 ng/ml (Group R0)
Study: 34560835
Drug: Remifentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil plasma target concentration 2 ng/ml (Group R2)
Study: 35131440
Drug: Sham CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham CPAP treatment
Study: 35020052
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 500 mg daily for 12 months
Study: 35416981
Drug: Exendin-(9-39) 0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin-(9-39) 0.44 mg/kg
Study: 35416981
Drug: Exendin-(9-39) 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin-(9-39) 0.6 mg/kg
Study: 35416981
Drug: Exendin-(9-39) 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin-(9-39) 0.6 mg/kg during MMTT
Study: 35416981
Drug: Exendin-(9-39) 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin-(9-39) 0.6 mg/kg during OPTT
Study: 32847444
Drug: Changweishu combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changweishu combined with routine Western medicine treatment
Study: 32847444
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western medicine treatments (meropenem, noradrenaline, glutamine glue, Bifidobacterium lactis triple‐strain tablet)
Study: 35760724
Drug: Stratified exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified exercise therapy (including dietary intervention for obesity subgroup)
Study: 35760724
Drug: Usual exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual exercise therapy (control)
Study: 35466705
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to Occupational Performance intervention (one hour weekly for 10 weeks)
Study: 32475989
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine infusion
Study: 35148626
Drug: Sterile polyacrylate
Normalized name: polyacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile polyacrylate wound pad with activated carbon cloth treatment
Study: 37522226
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg plus ezetimibe 10 mg
Study: 32664145
Drug: Bushen Yisui
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Yisui and Ziyin Jiangzhuo (BYZJ) granules administered twice daily for 4 weeks
Study: 32664145
Drug: Placebo (simulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (simulated granules) administered twice daily for 4 weeks
Study: 32055822
Drug: PF‐06412562 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06412562 (3 mg twice daily)
Study: 32055822
Drug: PF‐06412562 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐06412562 (15 mg twice daily)
Study: 35197189
Drug: No standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: No standardized delirium prevention and treatment measures (control)
Study: 34684351
Drug: Ginseng Extract
Normalized name: ginseng extract
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng Extract 3 g
Study: 36867173
Drug: Lithium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium augmentation
Study: 32957571
Drug: Quercetin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1000 mg/day)
Study: 35276922
Drug: High-quality, optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality, optimal protein diet (1.9 g·kg−1·d−1)
Study: 35276922
Drug: Adequate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate protein diet (1.2 g·kg−1·d−1)
Study: 34330599
Drug: Glucantime® +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime® + Oral Tamoxifen
Study: 33156688
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk for oral care
Study: 35322777
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution for oral care
Study: 32483675
Drug: 0.25% Timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% Timolol Gel
Study: 32483675
Drug: 0.5% Timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Timolol Gel
Study: 32483675
Drug: Carbonic Anhydrase
Normalized name: Carbonic anhydrase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbonic Anhydrase Inhibitors (CAI)
Study: 36273314
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg GCSF administered intrauterine with hCG injection
Study: 36273314
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered intrauterine with hCG injection
Study: 39076624
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA)
Study: 36368750
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g
Study: 36368750
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg plus 2 g azithromycin
Study: 32620345
Drug: Aurai water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurai water propelled, heating Eye Massager (AEM) used twice a day for 2 weeks
Study: 36237580
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese and Western medicine
Study: 38580946
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication
Study: 35486196
Drug: Discontinuous Treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous Treatment (DT)
Study: 33082194
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg once daily
Study: 35272176
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg modified release once daily (QD)
Study: 35272176
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg immediate release twice daily (BID)
Study: 33320381
Drug: Standard-dose ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ticagrelor (SD group, 90 mg twice daily)
Study: 33047732
Drug: S-P-BG group
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-P-BG group (5% STMP, 5% PAA, 0.5 g/L BG)
Study: 33047732
Drug: BG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG group (0.5 g/L BG)
Study: 32459375
Drug: Full-dose TKIs
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose TKIs